Citius Pharmaceuticals Inc（CTXR）財務資料CTXRCitius Pharmaceuticals Inc

Evaluating the bottom line, Citius Pharmaceuticals Inc maintains a gross margin of 67.07%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -785.39%, while the net margin is -797.92%. These profitability ratios, combined with a Return on Equity (ROE) of -70.29%, provide a clear picture of how effectively CTXR converts its operational activities into shareholder value.

In the context of the broader market, CTXR competes directly with industry leaders such as CTSO and MDXH. With a market capitalization of $15.10M, it holds a significant position in the sector. When comparing efficiency, CTXR's gross margin of 67.07% stands against CTSO's 73.18% and MDXH's N/A. Such benchmarking helps identify whether Citius Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Citius Pharmaceuticals has shown a notable increase in revenue, reporting $7.1 million in Q3 2026, primarily from the commercial sales of LYMPHIR, which indicates a growing market acceptance. However, the company has also faced substantial net losses, with a reported loss of $28.11 million in Q2 2026, reflecting ongoing financial challenges.